Clinical trials: SCHIZOPHRENIA 1 (Disorder)
Schizophrenia
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
This trial will determine the Pharmacokinetics, safety and tolerability of single-dose Aripiprazole administered intramuscularly in adults with schizophrenia
- Trial name
- NCT03150771
- Testing
- Aripiprazole
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tobacco Dependence, Schizophrenia
The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
Cigarette smoking represents a major health problem for patients suffering from schizophrenia. Compared to the general population, schizophrenic patients are significantly more likely to be addicted to nicotine.
- Trial name
- PSIAARP (NCT00495352)
- Testing
- Hihg-doseNRT, Low-dose NRT, bupropion
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- Yu-Li Hospital
Schizophrenia
Comparative Bioavailability of Risperidone.
This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
- Trial name
- NCT05179525
- Testing
- Risperidone ISM® 100 mg, Risperdal 4mg Tablet
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia, Metabolic Syndrome
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
- Conditions
- Schizophrenia, Metabolic Syndrome, Genetic Polymorphism
- Trial name
- NCT00717509
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National Hospital
Schizophrenia
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of multiple ascending oral doses of ASP4345 in patients with schizophrenia.
- Trial name
- NCT02720263
- Testing
- ASP4345
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cognitive Impairment, Schizophrenia
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
The purpose of this study is to determine if eltoprazine (as an adjunct to anti-psychotic medication) improves one or more aspects of cognitive impairment in adult schizophrenic patients.
- Trial name
- NCT01266174
- Testing
- Eltoprazine
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Amarantus BioScience Holdings, Inc.
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia or Schizoaffective Disorder
Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
- Trial name
- FIH (NCT02567370)
- Testing
- AMG 581
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amgen
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for healthy individuals, little…
- Conditions
- Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
- Trial name
- NCT00218218
- Testing
- Transdermal Nicotine Patch, 21 mg transdermal nicotine
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia / Schizoaffective Disorder
NST-SPARK Open-Label Phase 1 STTR (IGNITE)
Schizophrenia Spectrum disorders (SSD) are among the most devastating psychiatric disorders. Prominent negative symptoms such as low motivation, anhedonia, asociality, and emotional flattening are experienced by up to 60% of…
- Trial name
- IGNITE (NCT07593456)
- Testing
- NST-SPARK
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- North Shore Therapeutics, Inc.
SCHIZOPHRENIA 1 (Disorder), Substance Abuse
Comparison of the Italian and U.S. Forensic Models for Dual-diagnosis Offenders: a 3-year Longitudinal Study
This study aims to compare the Italian and U.S. forensic models in the treatment of offenders with dual diagnosis through a three-year longitudinal design.
- Trial name
- NCT07585656
- Volunteers
- 600 people
- Sponsor
- University of Bari
Schizophrenia
Study of CAD-9303 in Subjects With Schizophrenia
This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303.
- Trial name
- Affinity-1 (NCT04306146)
- Testing
- CAD-9303
- Where
- 2 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Cadent Therapeutics
Schizophrenia, Psychoses
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
After one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year.
- Trial name
- NCT00159120
- Testing
- maintained antipsychotic treatment vs. stepwise drug discontinuation
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Tobacco Use Cessation, Tobacco Use Disorder
Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1
Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a…
- Conditions
- Tobacco Use Cessation, Tobacco Use Disorder, Schizophrenia
- Trial name
- NCT00124683
- Testing
- Bupropion, nicotine transdermal patch
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia
Comparative Bioavailability of Risperidone
This is an open-label, one sequence study to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once daily 4 mg oral risperidone in subjects with schizophrenia…
- Trial name
- NCT03527186
- Testing
- Risperidone ISM® 100 mg
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio.
- Trial name
- P50 (NCT00725855)
- Testing
- MEM 3454
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memory Pharmaceuticals
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.
- Trial name
- NCT02331433
- Testing
- APN1125
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- CoMentis
Parasite and Infestation Physician-Patient Diagnostic Incongruency
The Parasite and Infestation Study
Many people have evidence of bugs, parasites, and infestation, but are told by others that they cannot find a cause. This distressing and frustrating experience can last for years, as the person seeks answers.
- Trial name
- NCT07849907
- Testing
- No intervention - observational study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults
The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.
- Trial name
- NCT07455084
- Testing
- 14C-SEP-380135
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.